Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: Final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study Academic Article Article uri icon

Overview

MeSH Major

  • Gastrointestinal Neoplasms
  • HIV Infections
  • Neuroendocrine Tumors
  • Pancreatic Neoplasms

abstract

  • This final analysis confirms that abiraterone acetate significantly prolongs overall survival in patients with metastatic castration-resistant prostate cancer who have progressed after docetaxel treatment. No new safety signals were identified with increased follow-up.

publication date

  • October 2012

Research

keywords

  • Academic Article

Identity

Digital Object Identifier (DOI)

  • 10.1016/S1470-2045(12)70379-0

PubMed ID

  • 22995653

Additional Document Info

start page

  • 983

end page

  • 92

volume

  • 13

number

  • 10